Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Ex-Minister Tamura Says Efficacy/Safety Confirmation Important in Emergency Approval, Wary on Macroeconomic Indexing
November 18, 2021
-
BUSINESS Otsuka’s Eczema Drug, 2 More Products Skip November Listing
November 18, 2021
-
BUSINESS Aducanumab Gets “Negative Trend Vote” in Europe: Biogen/Eisai
November 18, 2021
-
REGULATORY 50 Billion Yen-Plus Peak Sales Projected for Pfizer’s Vynmac, Listing Set for Nov. 25
November 17, 2021
-
COMMENTARY MOF, MHLW Push Conflicting Narratives on Drug Cost Control; Macroeconomic Indexing Is a Major Focus Too
November 16, 2021
-
REGULATORY Japan to Use mRNA Jabs for Boosters, Pfizer Vaccine for Time Being: Panel
November 16, 2021
-
BUSINESS Ono to Pay 28 Billion Yen to Settle Opdivo Feud with Honjo
November 15, 2021
-
REGULATORY Govt to Provide Up to 2 Billion Yen per Oral COVID-19 Drug to Support Development
November 15, 2021
-
BUSINESS Aikomi, Sumitomo Dainippon Eye Therapeutic App Approval for BPSD by 2027
November 12, 2021
-
ORGANIZATION Ex-MHLW Bureau Chief Calls for 6% Adjustment Rate, Frowns on Macroeconomic Indexing; Study Group Launch Next Month
November 11, 2021
-
REGULATORY Japan Approves Pfizer COVID-19 Vaccine for Booster Use
November 11, 2021
-
REGULATORY Japan to Receive 1.6 Million Courses of MSD’s COVID-19 Drug
November 11, 2021
-
BUSINESS Pfizer’s COVID-19 Vaccine Filed for Children 5 to 11 in Japan
November 10, 2021
-
BUSINESS 6 Wholesalers Raided over Suspected Bid-Rigging in Kyushu
November 10, 2021
-
REGULATORY Japan Drug Spending Up 2.3% Annually Since 2000, Outstripping GDP Growth: MOF
November 9, 2021
-
REGULATORY MHLW Panel Tables Decision on Efient’s Preventive Use for ICD Recurrences; Lilly's Migraine Med, Jardiance's Heart Failure Indication OK'ed
November 9, 2021
-
REGULATORY Chuikyo Calls for Combining Multiple Steps to Curb Spend for Potential Super Big Sellers Like Aducanumab, No Objection to Listing
November 8, 2021
-
REGULATORY Japan Approves Ronapreve to Prevent Symptomatic COVID-19
November 5, 2021
-
BUSINESS New EA Pharma CEO Eager to Put Company Back on Growth Track by Boosting Its Sales Strength
November 5, 2021
-
REGULATORY Ronapreve Clears Key Panel for COVID-19 Prevention, SC Use
November 5, 2021
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…